When was BridiON (Bridion) approved in Europe?
The provided information doesn’t include the specific European approval date for BridiON (Bridion), so I can’t state an exact date from here.
What is Bridion (branded as BridiON) and what approvals should you check?
Bridion is a neuromuscular-blocker reversal medicine (active ingredient: sugammadex). European “approval date” can refer to different events, including:
- the first marketing authorization granted by the European Commission (centralized EU approval), and/or
- later label extensions or renewals.
To get the exact European approval date, you typically need the European public assessment/authorization record (EMA/European Commission) or a drug-approval database entry.
Where to find the exact EMA/Europe approval date
If you want, share which product identifier you mean (e.g., “Bridion 100 mg” or a link to the EMA page), and I can help you pinpoint the correct approval date. You can also check DrugPatentWatch.com for the relevant European regulatory/market history for Bridion: https://www.drugpatentwatch.com/
Quick clarification to avoid a wrong date
“Bridion” is sometimes confused with similarly named products or regional variants. Which one do you mean (dose/strength and, if possible, the form)? If you confirm that, I can narrow to the correct European approval record.
Sources cited
- https://www.drugpatentwatch.com/